Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Akebia Therapeutics's Enterprise Value is €200.9 Mil.
Akebia Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €51.6 Mil. Therefore, Akebia Therapeutics's EV-to-OCF for today is 3.90.
The historical rank and industry rank for Akebia Therapeutics's EV-to-OCF or its related term are showing as below:
FRA:AX9'
s EV-to-OCF Range Over the Past 10 Years
Min: -408.44 Med: -1.88 Max: 22.15
Current: 3.79
During the past 13 years, the highest EV-to-OCF of Akebia Therapeutics was 22.15. The lowest was -408.44. And the median was -1.88.
FRA:AX9's EV-to-OCF is ranked better than 66.04% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.65
vs FRA:AX9: 3.79
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Akebia Therapeutics's PE Ratio (TTM) for today is calculated as:
Akebia Therapeutics's share price for today is €1.11.
Akebia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.069.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Akebia Therapeutics EV-to-OCF Related Terms
Akebia Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's EV-to-OCF falls into.
Akebia Therapeutics's current Enterprise Value is €200.9 Mil.
Akebia Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €51.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (FRA:AX9) has a EV-to-OCF of 3.90 as of Jul. 23, 2026. According to the industry distribution chart, Akebia Therapeutics ranks #342 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 34%.
Is Akebia Therapeutics' EV-to-OCF too high?
Akebia Therapeutics' current EV-to-OCF is 3.90. The Drug Manufacturers industry median EV-to-OCF is 10.65. Akebia Therapeutics' value of 3.90 is 63.4% below this industry median. Based on the distribution chart, Akebia Therapeutics ranks #342 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akebia Therapeutics has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' EV-to-OCF compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #342 out of 1007 companies for EV-to-OCF. This puts Akebia Therapeutics in the upper half of its industry. The industry median EV-to-OCF is 10.65. Akebia Therapeutics' value of 3.90 is 63.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.65, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current EV-to-OCF of 3.90 is 63.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current EV-to-OCF is 3.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (FRA:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.12, compared to a current price of €1.11 — trading 0.9% below its estimated fair value. The current EV-to-OCF is 3.90 and 63.4% below the Drug Manufacturers industry median of 10.65. Akebia Therapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Akebia Therapeutics (FRA:AX9), the current EV-to-OCF is 3.90 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (FRA:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €1.11 is trading 0.9% below its estimated GF Value™ of €1.12.
GuruFocus considers Akebia Therapeutics to be Fairly Valued.
Key valuation signals for FRA:AX9:
EV-to-OCF: 3.90
GF Value™: €1.12 vs. price of €1.11 (0.9% below fair value)
Industry Position: 63.4% below the Drug Manufacturers median (#342 of 1007)
No single metric tells the full story. See the FRA:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
55GF Score
Get the complete analysis for FRA:AX9
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AX9 has been successfully added to your 
